CClinicalTrials.gg
CompletedNCT02103452Updated Apr 4, 2014

Edessy Stem Cell Score (ESS), Endometrium, Endometrioma

An interventional study of Ovarian and endometrial samples in Endometriosis, Ovarian, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2014-04-04.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Purpose of this study is to evaluate stem cell expression (SCE) in endometriotic (E) and non endometriotic ovarian and endometrial tissues.

Read the detailed description

This study was conducted on 40 women at Al-Azhar University Hospitals. They are divided into two equal groups, group 1 with ovarian endometrioma and group 2 with normal ovary. Ovarian and endometrial samples were evaluated by hematoxlin \& eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE.

Evaluation of IH parameters revealed that the most important factors for evaluating SC were arranged as score ( Edessy Stem Cell Score=ESS).

02

Conditions studied

  • Endometriosis, Ovarian

Browse trials for

03

In context

Endometriosis

901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.

This study's enrollment of 80 is above the median of 64 across 525 interventional studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 20 to 40 years and did not receive hormonal treatment for three month

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus, cardiovascular and kidney diseases, adenomyosis, Uterine fibroid Endometrial carcinoma and Poly cystic ovary
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    ovarian endometrioma

    Ovarian and endometrial samples

    Procedure: Ovarian and endometrial samples

  • Experimental
    normal ovary

    Ovarian and endometrial samples

    Procedure: Ovarian and endometrial samples

Interventions

  • ProcedureOvarian and endometrial samples

    Ovarian and endometrial samples were evaluated by hematoxlin \&eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE

06

What researchers measure

Primary outcomes

  1. Edessy Stem Cell Score (ESS)

    ESS * Intensity of stem cell marker: Negative to mild =0, Moderate =1, Strong =2 * Percentage of stained cells: 0 =0, 0-50%= 1, \>50-100% =2. * Focality : None =0, Focal =1, Diffuse= 2 * Distribution: None= 0, Epithelial or mesenchymal= 1, Epithelial and mesenchymal= 2. * Localization of positive stained cell: None=0, Cytoplasmic or nuclear =1, Cytoplasmic and nuclear= 2

    Time frame: 1 week

07

Study locations

1 site
  • Al Azhar University
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02103452
Lead sponsor
Al-Azhar University
Responsible party
Edessy Mahmoud (Professor, Al-Azhar University) — Principal investigator
First posted
Apr 4, 2014
Start date
Oct 2012
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Apr 4, 2014

Study contacts

Mahmoud Edessy, MD
principal investigator · Al-Azhar University
Hala hosni, MD
study director · Cairo University
Magdy Olama, MD
study director · Al-Azhar University
Mohammad A Sattar, MD
study chair · Al-Azhar University
Ahmad Monir, MSc
study chair · Al-Azhar University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion